Who are Veronal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nembutal Sodium, Allonal, Metylfenemal, Thialpenton, Butenemal, Barbidorm.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/barbital.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Veronal — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Veronal (BARBITAL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: barbital. Area: Neuroscience.

phase 2 barbital Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Veronal (BARBITAL). Veronal works by enhancing the effects of the neurotransmitter GABA, which helps to calm the brain and induce sleep.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Veronal TARGET	BARBITAL		phase 2	barbital
Nembutal Sodium	PENTOBARBITAL	Oak Pharms	marketed	pentobarbital	GABA-A receptor alpha-1/beta-2/gamma-2	1973-01-01
Allonal	APROBARBITAL		marketed	aprobarbital
Metylfenemal	methylphenobarbital		marketed	methylphenobarbital	GABA-A receptor alpha-1/beta-3/gamma-2
Thialpenton	THIALBARBITAL		marketed	thialbarbital
Butenemal	VINBARBITAL		marketed	vinbarbital
Barbidorm	HEXOBARBITAL		marketed	hexobarbital	GABA-A receptor alpha-1/beta-3/gamma-2, GABA-A receptor alpha-2/beta-3/gamma-2, GABA-A receptor alpha-3/beta-3/gamma-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (barbital class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Veronal — Competitive Intelligence Brief. https://druglandscape.com/ci/barbital. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing